Results 21 to 30 of about 2,327,860 (219)

Baseline characteristics of patients who received recombinant tissue plasminogen activator for acute ischemic stroke.

, 2022
Baseline characteristics of patients who received recombinant tissue plasminogen activator for acute ischemic stroke.
Kitti Thiankhaw (13184005), Kanokkarn Teekaput (13184008), Surat Tanprawate (10298349), Chatree Chai-Adisaksopha (9200675), Chutithep Teekaput (13184002)   +4 more
core   +1 more source

Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems [PDF]

, 2003
Serine proteases, cysteine proteases, and matrix metalloproteinases (MMPs) are involved in cancer cell invasion and metastasis. Recently, a recombinant bifunctional inhibitor (chCysuPA(19-31)) directed against cysteine proteases and the urokinasetype ...
Sato, Sumito, Assfalg-Machleidt, Irmgard, Magdolen, Ulla, Schmitt, Manfred, Rettenberger, Peter, Magdolen, Viktor, Krol, Janna   +6 more
core   +1 more source

Successful Treatment of Arterial Thrombus in an Extremely Low-Birth-Weight Preterm Neonate

Pediatrics and Neonatology, 2013
Arterial thromboembolism in the pediatric population frequently occurs secondary to arterial catheterization. Catheterization-related complications are more common in smaller and sicker infants, due to high prothrombotic activity, low levels of natural ...
Petek G. Kayıran, Berkan Gürakan, Sinan M. Kayıran   +2 more
doaj   +1 more source

Recombinant tissue plasminogen activator for massive pulmonary thromboembolism [PDF]

BMJ Case Reports, 2013
Pulmonary thromboembolism (PTE) can result in significant adverse maternal and fetal outcomes. Monteplase—a recombinant tissue plasminogen activator—is considered effective for the treatment of PTE; however, only a few reports have described cases wherein surgical procedures were performed following treatment with monteplase. Here, we present a patient
Kouki, Samejima, Yasushi, Takai, Hideyoshi, Matsumura, Hiroyuki, Seki   +3 more
openaire   +2 more sources

Urokinase-Type Plasminogen Activator Promotes Paracellular Transmigration of Neutrophils Via Mac-1, But Independently of Urokinase-Type Plasminogen Activator Receptor [PDF]

, 2011
Background: Urokinase-type plasminogen activator (uPA) has recently been implicated in the pathogenesis of ischemia-reperfusion (I/R) injury. The underlying mechanisms remain largely unclear.
Paul J. Declerck, Rehberg, Markus, Daniel Puhr-Westerheide, Lerchenberger, Max, Uhl, Bernd, Kanse, Sandip, Johanna Liebl, Reichel, Christoph A., Bernd Uhl, Markus Rehberg, Zahler, Stefan, Lorenzl, Stefan, Elisabeth Deindl, Khandoga, Andrej, Declerck, Paul J., Stefan Zahler, Schmalix, Wolfgang, Fritz Krombach, Liebl, Johanna, Christoph A. Reichel, Krombach, Fritz, Max Lerchenberger, Andrej Khandoga, Stefan Lorenzl, Deindl, Elisabeth, Wolfgang Schmalix, Puhr-Westerheide, Daniel, Sandip Kanse   +27 more
core   +1 more source

Surgical management of submacular hemorrhage due to n-AMD: a comparison of three surgical methods

International Journal of Retina and Vitreous, 2020
Background To compare and assess the efficacy of three surgical methods for the treatment of acute submacular hemorrhage (ASH): pneumatic displacement with C2F6, in combination with intravitreal injection of bevacizumab and rtPA, pars plana vitrectomy ...
Carsten Grohmann, Spyridon Dimopoulos, Karl Ulrich Bartz-Schmidt, Philipp Schindler, Toam Katz, Martin S. Spitzer, Christos Skevas   +6 more
doaj   +1 more source

Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis [PDF]

, 2003
Pemphigus is an autoimmune blistering disease of the skin and mucous membranes. It is caused by autoantibodies directed against desmosomes, which are the principal adhesion structures between epidermal keratinocytes.
Besch, R., Wosikowski, K., Probst, C., Sander, C. A., Degitz, K., Schuh, T., Flaig, M. J., Braungart, E., Douwes, K., Magdolen, V., C.A. Sander, C. Probst, K. Wosikowski, K. Degitz, T. Schuh, R. Besch, E. Braungart, V. Magdolen, M.J. Flaig, K. Douwes   +19 more
core   +2 more sources

Defining Intravenous Recombinant Tissue Plasminogen Activator Failure [PDF]

Stroke, 2013
Although the 2 National Institute of Neurological Disorders and Stroke (NINDS) trials1 and subsequent studies from Europe (ECASS-3, IST-3)2,3 established intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rtPA) within 4.5 hours of symptom onset as an effective treatment for acute ischemic stroke, the ability of IV rtPA to ...
Waldo R, Guerrero, James C, Grotta
openaire   +2 more sources

Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II trials [PDF]

, 2009
<p><b>Background and Purpose:</b> A number of factors have been associated with postthrombolysis intracerebral hemorrhage, but these have varied across studies.</p> <p><b>Methods:</b> We examined patients with
Demchuk, A., Lees, K.R., Kasner, S.E., Messe, S.R., Cucchiara, B., Levine, S.R., Lyden, P., Sansing, L., Tanne, D.   +8 more
core   +1 more source

Hypersensitivity reactions to recombinant tissue plasminogen activator

Practical Neurology, 2019
Recombinant tissue plasminogen activator (rtPA) is currently the only approved thrombolytic agent for treating acute ischaemic stroke that is widely used in clinical practice. However, it may cause haemorrhage and hypersensitivity reactions. Orolingual angioedema is an infrequent, usually mild but potentially life threatening, hypersensitivity reaction
Vafa Alakbarzade, Declan O’Kane, Anthony C Pereira   +2 more
openaire   +3 more sources